{{Rsnum
|rsid=17007695
|Chromosome=4
|position=141788570
|Orientation=plus
|GMAF=0.1809
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 12.4 | 87.6
| HCB | 19.9 | 42.6 | 37.5
| JPT | 15.9 | 50.4 | 33.6
| YRI | 0.0 | 1.4 | 98.6
| ASW | 0.0 | 14.0 | 86.0
| CHB | 19.9 | 42.6 | 37.5
| CHD | 20.4 | 54.6 | 25.0
| GIH | 4.0 | 25.7 | 70.3
| LWK | 0.0 | 1.8 | 98.2
| MEX | 10.3 | 43.1 | 46.6
| MKK | 0.0 | 7.1 | 92.9
| TSI | 0.0 | 8.8 | 91.2
| HapMapRevision=28
}}[http://www.medpagetoday.com/HematologyOncology/Leukemia/12618 news] [[Leukemia]]

{{PMID Auto GWAS
|PMID=19176441
|Trait=Treatment response for acute lymphoblastic leukemia
|Title=Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
|RiskAllele=C
|Pval=9E-7
|OR=2.67
|ORtxt=[1.53-4.68]
|OA=1
}}

{{PharmGKB
|RSID=rs17007695
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (Initial Sample Size: 487 children; Replication Sample Size: NR); (Region: 4q31.21; Reported Gene(s): IL15; Risk Allele: rs17007695-C); (p-value= 0.0000009).This variant is associated with Treatment response for acute lymphoblastic leukemia.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740033
}}

{{PharmGKB
|RSID=rs17007695
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.10, combined P value= 8.85E-07. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470150
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17007695
|overall_frequency_n=13
|overall_frequency_d=122
|overall_frequency=0.106557
|n_genomes=11
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}